|
|
 Genentech and Novartis are developing an anti-IgE monoclonal antibody for asthma and allergic rhinitis. In December 1999 they announced positive study results. This is evidence that reducing IgE results in a reduction of symptoms associated with IgE-mediated europeantouch allergic disease.13 For people who find they cannot adequately avoid the allergens, the symptoms often can be controlled with medications. Effective medications that can be prescribed by a physician include antihistamines, topical nasal steroids, and cromolyn sodium - any of which can be used alone or in combination. Many effective antihistamines and decongestants europeantouch also are available without a prescription. Click here for allergy medication online. Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic europeantouch disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the europeantouch bloodstream before arriving at the liver. It is during this first pass in its native form that europeantouch it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels from europeantouch Day 0 to Day 30.3 Furnish your salon with our styling and shampoo stations. We have everything from manicure stations to foot spas. You can find retail display units, cabinets, and shelving for all of your storage needs.
|